Founder & CEOArie Laor
Seed Round
Aging is measurable. We built the instrument.
EXHLS has developed the first non-invasive biological age assessment platform using exhaled breath biomarkers — validated across 1,200 participants, with a 94% correlation to gold-standard epigenetic clocks.
We are raising seed capital to scale commercial operations, expand enterprise partnerships, and build the longitudinal dataset that makes EXHLS the definitive aging intelligence platform.
Traction
The numbers that matter.
Clinical validation participants — breath biomarker cohort
1,200
Correlation to gold-standard epigenetic clock (Horvath)
94%
Enterprise health system pilots in active deployment
7
Annual recurring revenue — current run rate
$2.1M
Leadership
Built by founders,clinicians, and engineers.
The EXHLS founding team unites clinical medicine, artificial intelligence, and precision software engineering — the disciplines required to commercialize breath-based biological age assessment at scale.
Full team bios, advisor network, and scientific advisory board available in the investor data room upon NDA execution.
Request data room →Use of funds
$2M deployed across three priorities.
Capital is allocated to the three activities that directly drive revenue and defensibility — commercial scale, clinical validation, and platform infrastructure. No allocation to overhead or non-revenue activities.
Commercial scale
Enterprise sales, consumer membership growth, and go-to-market infrastructure to convert pilots to multi-year contracts.
Allocation — $0.9M (45%)
- Enterprise sales team (8 FTEs)
- Consumer membership marketing
- Channel partnership development
- Customer success infrastructure
- Revenue operations tooling
Clinical validation
ELAS-2 longitudinal study, FDA 510(k) submission, and peer-reviewed publication pipeline to establish clinical-grade evidence.
Allocation-$0.6M (30%)
- ELAS-2 study (5,000 participants)
- FDA 510(k) regulatory submission
- Peer-reviewed publication pipeline
- Clinical site expansion (6 centers)
- Biomarker panel expansion research
Platform infrastructure
AI model development, data platform scaling, hardware device manufacturing, and enterprise integration infrastructure.
Allocation — $0.5M (25%)
- AI aging model v3 development
- Data platform (HIPAA-compliant)
- Device manufacturing scale-up
- Enterprise API and integration layer
- Security and compliance infrastructure
Investor relations
Accredited investors and institutional funds may request the full investor deck, financial model, and data room access.
This page does not constitute an offer to sell or solicitation of an offer to buy securities. Investment in EXHLS is available to accredited investors only.
Business model →